T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

The partnership aims to deploy AI capabilities that automatically analyse X-ray and CT images to assist radiologists.

Harald Hampel is recognized as an influential leader in neuroscience, and will bring expertise in Alzheimer's disease to BMS.

This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

Janux Therapeutics and Bristol Myers Squibb (BMS) are developing a tumor-activated therapeutic in an exclusive licensing agreement.

After several years of turning out solid growth, Bristol Myers Squibb knows it’s nearing a patent cliff that’ll wreak havoc later this decade. Still, the company believes a “diversified” ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...

Just in time for the annual American Society of Clinical Oncology (ASCO) meeting in Chicago, Bristol Myers Squibb launched a campaign to highlight its progress in dual immuno-oncology (I-O) research ...